Management of Hypnopompic Visual Hallucinations

Introduction

• Hypnopompic visual hallucinations are a condition characterized by recurrent, vivid visual hallucinations, often associated with some degree of vision loss, and can be managed with patient education and reassurance, as recommended by the American College of Physicians 1

Diagnosis and Characteristics

• Hypnopompic hallucinations are characterized by recurrent, vivid visual hallucinations, patient insight that what is seen is not real, and no other neurological or medical diagnosis explaining the hallucinations, often associated with some degree of vision loss 1
• The primary management of hypnopompic visual hallucinations should focus on patient education and reassurance about the benign nature of these experiences, as this approach alone often leads to significant relief and decreased anxiety in patients with some degree of vision loss 1
• Charles Bonnet Syndrome is a condition that occurs in 15-60% of patients with ophthalmologic disorders, characterized by recurrent, vivid visual hallucinations with preserved insight, and requires some degree of vision loss 1

Differential Diagnosis

• Distinguishing hypnopompic hallucinations from other conditions such as Dementia with Lewy Bodies, primary psychotic disorders, delirium, and narcolepsy is essential for proper management, as these conditions may present with similar visual hallucinations 2
• Infections (e.g., urinary tract infections, pneumonia), metabolic disorders (e.g., electrolyte imbalances, organ dysfunction), neurological disorders (e.g., cerebrovascular disease, traumatic brain injury, seizures), primary psychotic disorders (e.g., dementia with Lewy bodies), and intoxication and withdrawal syndromes (e.g., alcohol, hallucinogens, stimulants, cannabis) can cause hallucinations 3
• Dementia with Lewy Bodies (DLB) is characterized by visual hallucinations that occur in up to 80% of patients, often accompanied by cognitive fluctuations and parkinsonism, with hallucinations being a core diagnostic criterion 4
• Frontotemporal dementia, especially with C9orf72 mutation, can cause delusions and hallucinations in 21-56% of patients 5

Assessment and Evaluation

• The Neuropsychiatric Inventory (NPI) is used for hallucination assessment, and the Scale for Assessment of Positive Symptoms for Parkinson's Disease Psychosis (SAPS-PD) is used for assessing psychosis in Parkinson's Disease 4
• The North-East Visual Hallucination Interview (NEVHI) is used for assessing visual-domain hallucinations, and the Brief Confusion Assessment Method (CAM) is used for delirium diagnosis 4, 6
• A two-step process for delirium diagnosis is suggested, including a highly sensitive delirium triage screen and a Brief Confusion Assessment Method (CAM), according to the American College of Emergency Physicians 6
• Laboratory tests such as complete blood count, basic metabolic panel, liver function tests, urinalysis, blood cultures, and thyroid function tests may be indicated in specific situations to rule out underlying conditions 7, 8, 9, 10
• Neuroimaging such as head CT without IV contrast or brain MRI may be considered in patients with focal neurological deficits, abnormal neurological examination, atypical presentation or age of onset, first-episode psychosis without clear psychiatric cause, new or worsening headaches, history of head trauma, suspected stroke, seizure, or intracranial infection, or altered level of consciousness 11, 3

Management and Treatment

• Patient education and reassurance, including explaining the physiological basis of hypnopompic hallucinations and emphasizing their benign nature and common occurrence, can help reassure patients that these experiences do not indicate mental illness 1
• Self-management techniques such as eye movements, changing lighting conditions, and distraction techniques may be beneficial for patients with hypnopompic hallucinations 1
• Psychological therapies and support groups should be recommended for patients with vision loss and hypnopompic hallucinations 1
• Transcranial direct-current stimulation (tDCS) has shown promise in reducing hallucination frequency in patients with hypnopompic hallucinations 1
• Cholinesterase inhibitors (e.g., rivastigmine) have shown benefit for visual hallucinations in Dementia with Lewy Bodies 4
• Anticonvulsants, antidepressants, or benzodiazepines may be considered in selected cases of Charles Bonnet Syndrome, and transcranial direct-current stimulation (tDCS) has shown promise in reducing hallucination frequency in CBS 1
• Non-pharmacological approaches should be used first, including eliminating identified risk factors, fostering orientation, ensuring adequate pain control, and regulating bowel/bladder function, as recommended by the American College of Emergency Physicians 6
• Symptom control should include non-pharmacological approaches such as reorientation strategies, medication when appropriate, and avoiding physical restraints when possible 11
• A multidisciplinary approach should be taken, including neurology, physiotherapy, occupational therapy, speech therapy, and nutritional support 11

Prognosis and Outcome

• The overall mortality rate in patients with altered mental status is approximately 8.1% and is significantly higher in elderly patients 11
• Delirium is considered a medical emergency, and mortality can be twice as high if left undiagnosed 11
• Confusion in elderly patients often represents delirium, which affects approximately 25% of hospitalized geriatric patients and is associated with increased mortality, morbidity, and functional decline 6